BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36142172)

  • 1. Psychostimulants Modafinil, Atomoxetine and Guanfacine Impair Bone Cell Differentiation and MSC Migration.
    Wagener N; Lehmann W; Weiser L; Jäckle K; Di Fazio P; Schilling AF; Böker KO
    Int J Mol Sci; 2022 Sep; 23(18):. PubMed ID: 36142172
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chondral/Desmal Osteogenesis in 3D Spheroids Sensitized by Psychostimulants.
    Wagener N; Lehmann W; Böker KO; Röhner E; Di Fazio P
    J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis.
    Cortese S; Adamo N; Del Giovane C; Mohr-Jensen C; Hayes AJ; Carucci S; Atkinson LZ; Tessari L; Banaschewski T; Coghill D; Hollis C; Simonoff E; Zuddas A; Barbui C; Purgato M; Steinhausen HC; Shokraneh F; Xia J; Cipriani A
    Lancet Psychiatry; 2018 Sep; 5(9):727-738. PubMed ID: 30097390
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of ADHD medication in male C57BL/6J mice performing the rodent Continuous Performance Test.
    Caballero-Puntiverio M; Lerdrup LS; Grupe M; Larsen CW; Dietz AG; Andreasen JT
    Psychopharmacology (Berl); 2019 Jun; 236(6):1839-1851. PubMed ID: 30656365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Practitioner Review: Pharmacological treatment of attention-deficit/hyperactivity disorder symptoms in children and youth with autism spectrum disorder: a systematic review and meta-analysis.
    Rodrigues R; Lai MC; Beswick A; Gorman DA; Anagnostou E; Szatmari P; Anderson KK; Ameis SH
    J Child Psychol Psychiatry; 2021 Jun; 62(6):680-700. PubMed ID: 32845025
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overdose of drugs for attention-deficit hyperactivity disorder: clinical presentation, mechanisms of toxicity, and management.
    Spiller HA; Hays HL; Aleguas A
    CNS Drugs; 2013 Jul; 27(7):531-43. PubMed ID: 23757186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacologic treatment of attention deficit hyperactivity disorder in adults: A systematic review and network meta-analysis.
    Elliott J; Johnston A; Husereau D; Kelly SE; Eagles C; Charach A; Hsieh SC; Bai Z; Hossain A; Skidmore B; Tsakonas E; Chojecki D; Mamdani M; Wells GA
    PLoS One; 2020; 15(10):e0240584. PubMed ID: 33085721
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cognitive Effects of Stimulant, Guanfacine, and Combined Treatment in Child and Adolescent Attention-Deficit/Hyperactivity Disorder.
    Bilder RM; Loo SK; McGough JJ; Whelan F; Hellemann G; Sugar C; Del'Homme M; Sturm A; Cowen J; Hanada G; McCracken JT
    J Am Acad Child Adolesc Psychiatry; 2016 Aug; 55(8):667-73. PubMed ID: 27453080
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.
    May DE; Kratochvil CJ
    Drugs; 2010; 70(1):15-40. PubMed ID: 20030423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pharmacological management of oppositional behaviour, conduct problems, and aggression in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, and conduct disorder: a systematic review and meta-analysis. Part 1: psychostimulants, alpha-2 agonists, and atomoxetine.
    Pringsheim T; Hirsch L; Gardner D; Gorman DA
    Can J Psychiatry; 2015 Feb; 60(2):42-51. PubMed ID: 25886655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug prescription for attention deficit hyperactivity disorder drugs in pediatric outpatients: A retrospective survey of Japanese administrative data (2012-2018).
    Kikuchi D; Obara T; Tokunaga M; Shiozawa M; Takahashi A; Ito M; Hino H; Miura R; Hayakawa S; Watanabe Y
    Asian J Psychiatr; 2021 Mar; 57():102512. PubMed ID: 33486336
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Interactions of attention-deficit/hyperactivity disorder therapeutic agents with the efflux transporter P-glycoprotein.
    Zhu HJ; Wang JS; Donovan JL; Jiang Y; Gibson BB; DeVane CL; Markowitz JS
    Eur J Pharmacol; 2008 Jan; 578(2-3):148-58. PubMed ID: 17963743
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomized clinical study of a histamine H3 receptor antagonist for the treatment of adults with attention-deficit hyperactivity disorder.
    Weisler RH; Pandina GJ; Daly EJ; Cooper K; Gassmann-Mayer C;
    CNS Drugs; 2012 May; 26(5):421-34. PubMed ID: 22519922
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Guanfacine Extended Release: A New Pharmacological Treatment Option in Europe.
    Huss M; Chen W; Ludolph AG
    Clin Drug Investig; 2016 Jan; 36(1):1-25. PubMed ID: 26585576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Methylphenidate and atomoxetine normalise fronto-parietal underactivation during sustained attention in ADHD adolescents.
    Kowalczyk OS; Cubillo AI; Smith A; Barrett N; Giampietro V; Brammer M; Simmons A; Rubia K
    Eur Neuropsychopharmacol; 2019 Oct; 29(10):1102-1116. PubMed ID: 31358436
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of guanfacine: a postsynaptic differential approach to the treatment of attention deficit hyperactivity disorder (adhd).
    Alamo C; López-Muñoz F; Sánchez-García J
    Actas Esp Psiquiatr; 2016 May; 44(3):107-12. PubMed ID: 27254403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An Open-Label, Randomized Trial of Methylphenidate and Atomoxetine Treatment in Children with Attention-Deficit/Hyperactivity Disorder.
    Shang CY; Pan YL; Lin HY; Huang LW; Gau SS
    J Child Adolesc Psychopharmacol; 2015 Sep; 25(7):566-73. PubMed ID: 26222447
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Current pharmacotherapy of attention deficit hyperactivity disorder.
    Reddy DS
    Drugs Today (Barc); 2013 Oct; 49(10):647-65. PubMed ID: 24191257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cocaine-seeking behavior in a genetic model of attention-deficit/hyperactivity disorder following adolescent methylphenidate or atomoxetine treatments.
    Jordan CJ; Harvey RC; Baskin BB; Dwoskin LP; Kantak KM
    Drug Alcohol Depend; 2014 Jul; 140():25-32. PubMed ID: 24811203
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological treatment for Attention Deficit Hyperactivity Disorder (ADHD) in children with comorbid tic disorders.
    Pringsheim T; Steeves T
    Cochrane Database Syst Rev; 2011 Apr; (4):CD007990. PubMed ID: 21491404
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.